TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) will report its third quarter financial results for the period ended September 30, 2015 on Thursday, November 5, 2015 before the market opens.
Management of the Company will host a conference call to discuss these results and update investors on the status of its business on Friday, November 6, 2015 at 8:30 a.m. Eastern Time. Following the discussion, Acerus executives will address inquiries from investment analysts.
To access the call live, please dial 416-340-2219 or 1-866-225-2055. Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.
A replay of the conference call will be available until 11:59 p.m. Eastern Time on Thursday, November 12, 2015 by dialing 905-694-9451 or 1-800-408-3053, using access code: 2619492#.
Acerus Pharmaceuticals Corporation is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience.
Acerus markets ESTRACE® in Canada, a product indicated for the symptomatic relief of menopausal symptoms. NATESTO™, a product utilizing an Acerus licensed nasal gel technology, is the first and only testosterone nasal gel approved and launched in the United States for replacement therapy in adult males diagnosed with hypogonadism, and is currently filed for approval in Canada. The commercial rights to NATESTO™ in the United States and Mexico have been licensed by Acerus to an affiliate of Endo International plc. TEFINA™, a ‘use as required’ nasal testosterone gel, is an Acerus drug development candidate aimed at addressing a significant unmet need for women with female orgasmic disorder.